Diagnosis, treatment and support
Other women's good results in no way diminish the hurt that
mesh has caused them and you...I recognise that we have not informed you well
enough about treatment choices or complications or their management. It's a truth
sadly borne out by the recurrent themes being heard of mesh offered as the only
choice; potential mesh complications inadequately, or sometimes not at all,
discussed; and feeling ignored when complications do arise.
This chapter considers women's experience of the clinical pathways for
treatment of stress urinary incontinence (SUI) and pelvic organ prolapse (POP)
using transvaginal mesh procedures.
Evidence to the inquiry has raised a range of concerns regarding women's
engagement with medical practitioners. Women raised concerns regarding the
information they received prior to transvaginal mesh surgery and the treatment
and support they received when they presented with complications. The committee
was told that many women 'have been left utterly traumatised by their doctor's
lack of knowledge, understanding and compassion.'
The evidence received during the inquiry is consistent with the findings
of a series of consumer consultation forums undertaken by the Australian
Commission on Safety and Quality in Health Care (ACSQHC).
Key concerns raised by women attending the ACSQHC forums included the
following concerns about their engagement with medical practitioners:
the need for greater clarity regarding patient selection for POP
and SUI procedures;
concerns regarding women's ability to provide their informed
consent prior to surgery and the need for more accessible information
concerning the potential complications resulting from transvaginal mesh
recognition by general practitioners (GPs) and specialists of
complications relating to transvaginal mesh.
Medical practitioners, including those who spoke in support of the use
of urogynaecological mesh in the treatment of SUI and POP, have also emphasised
the importance of patient selection, informed consent, and post-operative
The committee notes that the ACSQHC forums also identified the need for
training and credentialing support for clinicians and the development of
guidance for health services organisations and consumers in relation to
complications associated with transvaginal mesh implants and its removal. These
matters will be considered in Chapter 5.
A great deal of evidence to the inquiry has centred on the extent to
which women have received appropriate information to assist them to give their
informed consent prior to transvaginal mesh procedures.
Common law requires medical practitioners, as part of their duty of
care, to provide patients with information necessary to give consent to
treatment, including information on all material risks of the proposed
What constitutes informed consent?
The committee was told that as well as being a legal requirement, the
Royal Australasian College of Surgeons' (RACS) Code of Conduct requires
surgeons to fully inform patients and obtain consent from the patient (or a
substitute decision maker). RACS has stated that patients should be well
informed of all risks associated with their surgery and surgeons should assist
patients in selecting the form of treatment most appropriate to their
particular situation. RACS has also stated that '[s]urgeons need to be able to
counsel their patients about the range of options available and tailor
treatment to the patient's needs, not their skill base as a surgeon.'
In its submission to the inquiry, the Royal Australian and New Zealand
College of Obstetricians and Gynaecologists (RANZCOG) stressed that, while
standard consent forms are used, 'consent is more the process of consultation
between the individual woman and her treating doctor.' RANZCOG stated:
In the case of transvaginal mesh, it would be expected that
the treating surgeon explains the treatment options, both non-surgical and
surgical, the permanent nature of synthetic mesh and the likely success rates
considering the individual woman's clinical factors. It would also be expected
that possible risks be explained including general surgical risks and the risks
specific to mesh implants ...
Submissions from specialist medical colleges and sub-specialist urology
and gynaecology units stressed the comprehensive nature of counselling provided
to women prior to surgery. The Urological Society of Australia and New Zealand
(USANZ) submitted that the standard of care is for routine pre-operative
counselling to be undertaken prior to surgery by specialist urologists. USANZ
acknowledged that the depth and nature of such counselling will vary between
individual specialists and the health services they work within. Specialists
may use pre-printed patient information sheets developed by professional bodies
or their own personal or health service based, documents. USANZ advised that
the framework for pre-operative counselling discussions would comprise:
the rationale for treatment;
treatment options, including non-surgical and non-mesh options;
the likely success and potential complications, with particular
emphasis on those that may impact the individual being counselled; and
the opportunity to ask questions.
USANZ referred the committee to the American Urological Association
(AUA) Surgical Treatment of Female Stress Urinary Incontinence (SUI):
AUA/SUFU Guideline, and noted
the 'AUA guideline specifies "prior to selecting
midurethral synthetic sling procedures for the surgical treatment of stress
urinary incontinence in women, physicians must discuss the specific risks and
benefits of mesh as well as the alternatives to a mesh sling." It also
acknowledges specific risk groups for whom mesh complications may be more
common, in particular diabetes and a history of smoking.
USANZ also noted that the AUA guideline recommends that patients be made
aware of prior United States Food and Drug Administration public health
notifications regarding the use of transvaginal mesh and be advised of possible
The Urogynaecology Units at the Mercy Hospital for Women and Monash
Health, which are subspecialty, multidisciplinary, gynaecology units, advised
the committee that women presenting with urinary incontinence receive advice on
conservative, non-surgical options as first-line treatment. Where these are
unsuccessful, patients receive comprehensive counselling about surgical
options, including: the nature of polypropylene mesh; cure and satisfaction
rates; information about the transvaginal procedure for the insertion of a
mid-urethral sling and information about the incidence of relevant surgical
The Urogynaecological Society of Australasia (UGSA) provided the
committee with copies of information leaflets developed by UGSA, RANZCOG and
the International Urogynaecological Association which it said urogynaecologists
and gynaecologists in Australia generally provide patients. These leaflets
address a number of aspects of treatment for pelvic floor dysfunction including
information on alternative management options and conservative non-surgical
treatment, surgical treatment with and without mesh, and complications with
mesh and non-mesh procedures.
Associate Professor Jason Abbott, President of the Australasian
Gynaecological Endoscopy and Surgery Society, stressed the importance of
doctors ensuring that women understand the information that is provided to
Generally speaking, we recommend that we always ask the
questions: 'Do you understand? Do you have any other questions? Do you have any
concerns? Is there anything specific that you would like to know regarding this
procedure?' I think that goes with all medical procedures. It's very important for
us to have a depth of understanding as to what our patients think of a
particular procedure and what they think is important. We don't always get that
right. I think that in this situation we haven't always got that right.
The reality of the consent process
Some submitters and witnesses expressed doubt regarding the level of
information provided to women prior to surgery. The Australian College of
Midwives (ACM) submitted that, in their experience, many women receive very
little information prior to their surgery and expressed concern that there are
few sources of consistent information available to women in terms of surgery.
The ACM told the committee that information provided prior to surgery should
include the specialist doctor's experience and training with the procedure as
well as the known complications associated with mesh implants published by the
TGA. The ACM stated that women rarely have access to full information about the
surgery because very few hospitals or specialist doctors make their rates of
complications publicly available and very few specialist doctors provide
information about their own level of skill and training with specific
The Australian Pelvic Mesh Support Group (APMSG) told the committee that
a survey of its members, based on the guidance provided in RANZCOG's statement Polypropylene
vaginal mesh implants for vaginal prolapse,
concluded that the majority of women have not been asked any of the questions
suggested by RANZCOG. Ms Carolyn Chisolm, Founder of the APMSG, told the
The first question was, 'Did your specialist tell you, due to
the withdrawal of some of the commonly performed and studied transvaginal mesh
products from the market, that very limited robust data is available on the
efficacy and safety of the transvaginal mesh products available in
Australasia?' Out of 104 responses, 100 per cent said no.
The second question was: 'Did your specialist tell you that
patients with asymptomatic prolapse do not necessarily require surgical
management and that the decision to operate should be based upon symptomatic
bother from the prolapse, defined by the patient? There is little longitudinal
data in the literature on untreated asymptomatic prolapse to inform a decision
for surgery in this situation.' Ninety-five point two per cent said no.
'Did your specialist tell you there are alternatives to
surgical management, including non-surgical options such as pelvic floor muscle
training, for mild prolapse, and vaginal support pessaries?' Seventy-nine point
eight per cent said no.
'Did your surgeon tell you that complications of transvaginal
mesh include mesh exposure, erosion, vaginal scarring, stricture, fistula
formation, dyspareunia—which is painful sex—and/or unprovoked pelvic pain at
rest and the possibility of mesh surgery resulting in unprovoked pelvic pain at
rest that can be difficult to treat?' One hundred per cent said no.
'Did your surgeon tell you, if mesh complications arise, this
may require additional surgical intervention and the complications may not
completely resolve, even with mesh removal?' Ninety-eight per cent said no.
'Did your surgeon tell you that complete removal of the mesh
implant may not always be possible?' Ninety-eight point one per cent said no.
The Health Consumers Councils across Australia (HCCs) also undertook a
survey and reported that 40 percent of women who responded did not consider
they were fully informed and 22 percent stated they were given some
information, but that the outcome of the surgery was not as suggested.
The HCCs noted that this is not the first instance in which informed
consent processes have been found to be poor, and referred to the findings of
the committee's inquiry into the role of the TGA regarding medical devices in
in which the committee recommended:
Rigorous systems be put in place to ensure that medical
practitioners provide consumers with all the information needed to allow them
to give fully informed consent.
The HCCs expressed disappointment with the government response to the
report and expressed the view that the practice of relying on doctors to pass
on information to patients has not worked to ensure women are able to make
Information provided to women prior
to transvaginal mesh procedures
The personal accounts of women who wrote to the inquiry generally do not
reflect a process of thorough counselling and informed consent.
The committee is aware that some care may be needed in reviewing
patient's recollections of information provided to them prior to surgery. Associate
Professor Jason Abbott, President of the Australasian
Gynaecological Endoscopy and Surgery Society, told the committee that it
can be difficult to communicate the extent and breadth of information that is
important to a particular patient. He observed that patients who have not
experienced any complications with a device may feel that they have been
adequately informed, while the situation may be different for patients who have
sustained injury, are in chronic pain and require repeat procedures.
It's one thing to give facts and figures, to say that the
number of women who might have a problem from this particular procedure are one
per cent, two per cent, 10 per cent or 50 per cent and how that might have an
impact. It's another to get that recollection from the woman.
Dr Jane Manning, a urogynaecologist in private practice, expressed the
view that detailed preoperative counselling on all the major surgical risks is
routinely provided to patients, but patients do not expect complications will
happen to them. She stated that it is difficult for pre-operative counselling
to adequately prepare a woman for the eventuality that she could develop lifelong
disabling pain, or to convey what chronic pain will be like when it occurs. She
also submitted that as evidence available to surgeons suggests the risk of
chronic pain is low following transvaginal procedures, they may not emphasise
this in preoperative counselling.
The committee notes that some women have expressed satisfaction with the
level of information they received. One woman, who had successful transvaginal
mesh surgery in the treatment of SUI five years ago, told the committee:
All operations carry the risk of failure or complications,
and even death, but the individual must make their own decision regarding what
risks they are prepared to take for the sake of improved health. These risks
are explained by the operating surgeon and, as you are aware, the medical consent
form states that there is an element of risk. The patient is asked to read and
sign this consent form thereby acknowledging that they are aware of those risks
and that they are prepared to accept them.
Limited and generic information
The majority of women who provided personal accounts to the inquiry told
the committee they had received little or no information prior to their
One woman who received her implant in 2007 wrote:
Prior to my first surgery I was told briefly of some
complications and shown a small piece of mesh. I was told that only a very
small percentage of women have complications, for instance some women had pain
with sexual intercourse after surgery, and that the [redacted] could cause
stress incontinence but this was easily fixed with another surgery where a
[redacted] sling could be inserted. It was not made clear that there could be
very serious, life-changing and life-threatening complications. I was not told
that the mesh was unable to be removed if there were problems.
Many women recall being told simply that the procedure was safe, minimally
invasive and uncomplicated.
For example, one woman who underwent a transvaginal mesh procedure for the
treatment of SUI in 2010 was told that:
this was the "Gold Standard" in treating SUI, was a
day procedure, very safe and came with only minor risks, those being the
standard risks associated with all surgeries (reaction to anesthetics, blood
loss, small risk of infection or rejection.
Some women provided the committee with copies of the information they
were given, highlighting that this information did not include discussion of
the complications they had experienced:
One of the most infuriating aspects of this experience is not
being provided any information about the Mesh before the first operation and
only a printout given out regarding the operation. There was no information
provided referring me to the complications of the Mesh...I would not wish for any
woman to go through this experience or be treated in this manner due to a
failure in information and product.
In many cases, a transvaginal mesh procedure appears to have been the
only treatment option offered.
One woman, who received a transvaginal mesh implant in 2008 as treatment for a
prolapse bladder, told the committee:
Dr [redacted] who performed the surgery, seemed convinced
that not only was this the best option, he lead me to believe this was the only
option for me. No other options were communicated with me and at no time was I
made aware that this device could fail.
Another woman who received her implant in the treatment of minor incontinence
in 2014 wrote:
Being an educator, I chose an Associate Professor Urologist
because I felt confident that he would have the 'latest and best' in practice
and information. After a round of urodynamic testing, a short trial of tablets,
it was recommended that I have tape to lift my bladder so the urine would not
tip out. I watched a video on my surgeons website that promoted an attractive
energetic woman jumping on a trampoline with her family. I believed that the
surgeon could make me just as active and carefree as the portrayed woman. I was
not offered any other surgery other than this tape. I was warned that there was
1% risk that I may not be as dry as I would like.
Lack of awareness that a mesh
implant was being proposed
Some women were not informed that a medical device was being implanted
as part of their surgery.
Mr Danny Vadasz, Chief Executive Officer of the Health Issues Centre, told the
committee that many women were not told that they had a mesh implant until they
began to experience complications. He said:
For many women, they were never told that they had had a mesh
implant until they identify symptoms which they recognise to be associated with
mesh implants and on further investigation they discover they do. Many women
still do not know, because they cannot retrieve their medical records. Some
have had to go freedom of information in order to retrieve their records. That
is a very significant problem.
Other women were not advised that the 'sling' or 'tape' being used in
their surgery was in fact polypropolene mesh.
As one woman, who had received a tension-free vaginal tape-obturator device in
the treatment of SUI in 2014 and had a Sacrocolpopexy later the same year in
the treatment of POP, explained:
I had the same specialist for both of these operations and at
no time was mesh mentioned, my doctor called it tape. In my mind I imagined it
was something similar to the tape that is put over the cotton ball after a
blood test. I was not given any information on the damage this tape, mesh could
cause. I had no idea that I was having mesh put inside my body! I think that
the obvious thing that women should be told before surgery is - the exact
nature of the complications that could occur with this mesh, which would allow
them to make a carefully thought out decision knowing what the consequences
could be of having this mesh implanted. Unfortunately the majority of people believe
wholeheartedly what a doctor tells them to do and so don't listen to the doctor
as carefully as they should.
One woman wrote on behalf of her mother who had unknowingly received a
transvaginal mesh implant while undergoing surgery for a vaginal hysterectomy
in 2009. In this case, the woman had been invited to participate in a trial
that the surgeon was undertaking and had declined to take part.
Two weeks ago my mother became aware through hospital records
that while in surgery for a vaginal hysterectomy a transvaginal mesh device was
inserted. My mother's legal and ethical rights, to provide informed consent for
this device were ignored. Prior to surgery my mother was not informed a medical
device was being implanted, nor was she informed prior or post surgery about
possible complications associated with this medical device.
Another woman, who had experienced debilitating pain and unexplained
episodes of bleeding following vaginal repair surgery in 2015, was prompted to
seek clarification of whether she had received a mesh implant after reading an
article about complications associated with transvaginal mesh implants. Her
doctor was able to confirm this. She told the committee:
At that point I felt completely doomed I put the puzzle
together and started crying. How can I have not known a foreign medical device
had been implanted in my body without my consent? If I had known I would have done
my research and not agreed in the first place. Since at that time there was so
many issues regarding this matter.
A number of women were not informed that the implant is intended to be
permanent and that in the event of complications, removal can be difficult.
One woman who had transvaginal mesh surgery in 2004 to address her minor
incontinence told the committee of her horror when she learnt that the mesh was
When I returned to my surgeon, I asked about a recent
incident when I bent to pick up something and I felt a sharp pain in my left
side accompanied by a loose feeling and a "ripping sound". My surgeon
told me that this did not indicate any reason for me to be concerned because
the implant 'would have grown in by now'. I was horrified as I believed that
the mesh implant could be easily removed. I asked what she meant by 'grown in'
and I was then given a pamphlet and more detailed information about the
procedure, including the fact that the mesh grows in to body organs. I'm
confident that had I received this information at the initial consultation, I
would not have had the surgery as my incontinence was minor.
Limited opportunity to ask
Some women told the committee that they had sought to make an informed
decision by asking questions of their implanting surgeon and had given their
consent, based on the trust they felt for the medical practitioner. A Registered
Nurse told the committee that upon being advised to have a hysterectomy and
repair operation, she had researched the mesh involved and found them to be
controversial. She raised her concerns with her doctor who dismissed her
I then brought this to the attention my doctor and strongly
voiced that I did not want the mesh. My Doctor then emphasised that with the
level of exercise I do and how active my lifestyle was, he would not be doing
the right thing by me if he did not use the mesh.
He did not inform me of any side effects of the mesh, or
state any history of complications involving the mesh; therefore my initial investigations
were dismissed, as the doctor described the operation to not involve any
issues, meaning the complications for a hysterectomy were overlooked. Due to
the respect and trust I "had" for our medical industry, I signed a
consent form, under the impression a "professional" had confidently
dismissed the concerns I voiced.
Some women indicated that they felt pressured to agree to the surgery.
One woman told the committee that she attended for a routine pap smear and
mentioned that she experienced SUI:
Straightaway, like a 'Jack In The Box', he popped his head up
from between my legs, "I can fix your USI" and subsequently did his
utmost to convince me that I needed what he described as, "a safe and
simple straight forward, minimally invasive, uncomplicated and effective
surgery". I made it clear that should I agree, I wanted the surgery done
privately, but he discovered I had no private health cover and said, "I do
the very same surgery in the XXX [sic] so I'll do it there".
Another woman told the committee that her doctor had shown what she
considered to be unusual eagerness to perform transvaginal mesh surgery even
though she was not aware that she had any symptoms of POP:
There was pressure on me to agree on that same day to the
transvaginal mesh surgery. It was explained to me that if I declined and that
surgery was still needed, it would be a lengthy delay before I could reapply to
have it done. And it was more efficient to have one operation with two
procedures than to have two separate operations. I believe my mesh implant was
therefore unnecessary and my years of suffering afterward could have been
Many women who wrote to the committee said that they had trusted the
judgement of their medical practitioners.
As the following statements indicate, women trusted the advice of their GPs who
suggested that a particular surgeon was 'very good' and they trusted the advice
and opinions of the specialists they saw.
The specialist is an experienced urologist, so I trusted his
advice/opinion. I did not investigate his experience in that area, but was
reassured by my GP that he was very good.
Improving the consent process
The Public Health Association of Australia (PHAA) summed up the views of
many submitters to the inquiry by saying that it is the doctor's duty, at the
point of care, to inform a patient of all potential adverse outcomes associated
with transvaginal mesh products and to be aware of any substantial risk factors
that could exclude the use of transvaginal mesh to treat a patient. The PHAA
Patient counselling is very much reliant on effective
communication between a woman and her clinician and we know from all other
areas of clinical care that it calls for a woman centred approach to shared
decision-making. Consideration needs to be given to the development of
education and decision-making tools with regard to pelvic mesh to really
facilitate a shared understanding of the woman's health issue in order to
generate a mutually acceptable evaluation and management plan, that as
complications arise they can be identified and acted upon early in the stages
after implementation. These tools and education materials not only ensure
informed decision-making but they also, really importantly, ensure informed
Women told the committee that much more information needs to be provided
to women prior to surgery regarding potential complications and alternative
options. Women emphasised that this information needs to be explicitly and
thoroughly communicated before they undergo surgery.
One woman echoed the sentiment of many of the women who provided personal
accounts to the committee:
Women need to be empowered to make an INFORMED decision prior
to receiving a transvaginal mesh implant. In order for this to occur, ALL
available treatment options (including non-surgical and other alternative
treatment methods) need to be discussed at length, as well as the variety of
short- and long-term adverse effects of mesh implants and implications for
A medical practitioner who was the recipient of a transvaginal mesh
implant told the committee that her expectation was that a doctor would not
only list the possible risks of the proposed surgery, but discuss how likely
they are to occur. She called for the preparation of standardised consent
forms, stating that while this is no substitute for good verbal communication
between the doctor and patient, it would at least standardise the basic
information given to patients and allow them to make a more informed decision.
Other women recommended that information be made available on a
My hope is that there would [be] a government web site that
people could go to get accurate information. This would be about operations
that have had adverse out comes and ones that have been found to be successful.
That way we could all make informed consent.
Diagnosis - selecting the right procedure for the right patient
As noted in earlier chapters, the committee has consistently been told
that SUI and POP can be complex conditions to treat and that medical
practitioners need access to a range of treatment options to provide an
appropriate level of care.
Associate Professor Abbott told the committee that there is potentially a place
for transvaginal mesh procedures undertaken by the right surgeon, in the right
patient, for the right clinical scenario.
However, the committee heard that a significant problem, particularly
with the use of transvaginal mesh in the treatment of POP, has been poor
Professor Hans Pieter Dietz told the committee that he considered transvaginal
mesh had been overused and that in many cases, its use has been based on
From my point of view, of those 40 cases, there were 20 or so
that were urogynaecological; and maybe one or two of those in 20 patients had
had the full diagnostic workup that I would consider appropriate. The vast
majority had major gaps in their preoperative diagnostic workup. The reason for
that is that urogynaecology, from its very start, has been a surgical
specialty. Urogynaecologists are surgeons first and foremost and we simply have
not been using the technologies that modern imaging provides us with. In some
instances, we have not even used the full options that are given to us by our
eyes and our hands. We have not been very good at examining those women.
The committee also heard that there was an overenthusiastic uptake of
transvaginal mesh devices. Dr Jenny King told the committee:
Look, you're right. The slings were a hell of a lot better than
what we had before and then when the meshes came along we all thought, 'Yes.
There will be no more failures. We're going to be able to fix everyone.' And I
think it did. It got over used overenthusiastically. A lot of stuff we did not
Associate Professor Christopher Maher, told the committee that it is
important to examine the role of clinicians and sponsoring companies in the
introduction of new devices. He prefaced his comments by stating:
There's no doubt that all of my colleagues who utilised these
products and who were very early adopters of these medical devices for the
treatment of prolapse did so in the hope of obtaining improved clinical
outcomes for their patients.
Professor Maher noted that the interaction between sponsoring companies
and leading clinicians in the introduction of new transvaginal mesh products
may have contributed to overuse of the devices:
Once these products are utilised and allowed by the TGA,
we're able to utilise them pretty freely. The sponsoring companies actively
promote medical specialists who utilise their products to referring GPs and
company-sponsored educational activities, where one of the aims of that
activity is to increase utilisation of those products. Sponsoring companies are
also actively involved in the education and provision of training to medical
While noting that none of these activities are illegal or inappropriate,
Professor Maher noted that the provision of education or training to
specialists and GPs should be conducted at arm's length and the nature and
extent of any financial conflict should be declared.
Selecting a treatment option
Evidence from specialist colleges and specialist medical units, outlined
a careful process of assessment and diagnosis for women presenting with pelvic
floor dysfunction. For example, Monash Health, a specialist unit of
urogynaecologists and gynaecologists, submitted that when women present with POP,
a thorough history and examination is undertaken before first line treatment
options are discussed. First line treatment options include pelvic floor muscle
rehabilitation and conservative management with pessaries.
If there is no improvement surgical options are discussed. For women who
present with POP for the first time, the usual surgical management is native
tissue repair. Monash Health submitted that transvaginal mesh is offered as a
surgical option only in very selected cases, such as women presenting with
recurrent pelvic organ prolapse who have failed previous surgery and
conservative management. In the last 12 months Monash Health has mainly
performed transvaginal mesh surgeries when transabdominal mesh surgery was
unable to be performed. 
RANZCOG submitted that while conservative treatments may be helpful, in
many cases surgical intervention is either requested or required. RANZCOG said:
It has long been recognised that surgical treatments for
these conditions (especially POP) are not always successful, particularly in
the long term, and surgeons have tried many different surgical approaches in
the attempt to minimise the disappointment and distress of women having a
premature recurrence of their prolapse that might need further surgery.
The Continence Foundation of Australia (CFA) submitted that non-surgical
measures, such as pelvic floor muscle training and behavioural therapies,
should always be the first line treatment options for SUI. However, when these
treatment options are unsuccessful, surgical intervention may be indicated and
can be highly effective.
Dr Alison de Souza, a urogynaecologist with the Mercy Hospital for
women, explained that, at the Mercy Hospital, the first line management of SUI
is conservative and non-surgical. Women are prescribed pelvic floor muscle
exercises and/or incontinence aids, such a vaginal pessaries. She stated that
approximately 50 per cent of women 'will have a subjective cure of their
symptoms with physiotherapy.' Where physiotherapy does not address the
symptoms, surgical options are considered.
The committee was told that mid-urethral slings (MUS) are the most
common surgical treatment for SUI and the procedure has been extensively
reviewed and found to have a good safety profile.
RANZCOG submitted that when compared to alternate procedures, such as the Burch
colposuspension, urethral injection and suprapubic sling without mesh, MUS was
found to carry a lower overall risk of complications.
As noted in Chapter 2, a number of the women who have provided personal
accounts to the committee have reported experiencing significant complications
Dr Michelle Atherton, a urogynaecologist working in private practice, told the
committee that the reason there are a lot of women with complications following
MUS is because 'stress incontinence mesh is used as a first line procedure
because there is no other good procedure'. She stated that alternative non-mesh
treatments have significant failure rates and higher complication rates.
Dr De Souza explained that a number of factors made some alternative
surgical procedures difficult for women to access. She said the pubovaginal
fascial sling and some Burch colposuspension procedures can involve large, open
cut abdominal surgery, with longer hospital stays, prolonged recovery time and
delayed return to work. She said that bleeding, wound and bladder infections,
increased risk of blood clots, significant difficulty emptying the bladder,
subsequent prolapse and pain are well known complications of these procedures.
The committee was consistently told that transvaginal mesh should not be
used as a first line treatment for POP. Dr Atherton told the committee that
transvaginal mesh for the treatment of prolapse is a high-risk product and
should only be used in certain circumstances and only by subspecialist
urogynaecologists. She said:
The return-to-theatre rate offsets the
improved-prolapse-recurrence rate in the woman who has an average risk of
prolapse recurrence, which is about a 20 per cent risk of recurrence. Because
of this, it should really be reserved only for specific circumstances where
there are very, very high risks of recurrence—such as somebody who has had two
or three or four prolapse recurrences. We are dealing, in our urogynaecology
clinic, with women—and I saw one just yesterday—who have prolapses that come
out up to 10 centimetres; they are swollen; they are ulcerated. They have
failed multiple previous native tissue—own tissue—repairs. A lot of them are,
medically, not really fit for having a big abdominal procedure.
Dr Atherton noted that mesh inserted abdominally for the treatment of
prolapse is a lesser-risk product, but still carries a two to four percent
risk. However, she explained that abdominal procedures are mainly used for
prolapse of the vaginal vault.
The ACSQHC told the committee that, consistent with the best
international evidence, it had reached the view that transvaginal mesh should
only be used in a research context, due to uncertainty about long-term effects
and risk of complications.
Representatives of the Therapeutic Goods Administration explained that the
publication of the results of two very large studies in the last 12 months
comparing transvaginal mesh and native tissue procedures
had turned the tide for the use of transvaginal mesh as a first line treatment
Ms Adriana Platona, told the committee:
We have had uncontroverted evidence about the unfavourable
benefit and risk profile for this product for pelvic organ prolapse when used
transvaginally, when inserted via the vagina, and we are acting on that
Dr Gary Swift, President of the National Association of Specialist
Obstetricians and Gynaecologists, told the committee that this posed a
difficulty for medical professionals:
The difficult thing now that we see is what place mesh should
occupy going forward. There is a risk of taking away an option that potentially
may be of a very positive benefit to some women, but obviously at the expense
that some women are at risk of significant adverse effects...There is also the
issue of mesh sacrocolpopexy, as Dr Dowling has mentioned. Apical vaginal
prolapse is a particularly difficult issue and without mesh an incredibly
difficult condition to treat. We see that if there was a risk of us losing the
ability to offer some of these treatments to women, there is a potential for
suffering from the lack of ability to treat some of these more significant
As noted earlier, accounts from individual women indicate that transvaginal
mesh procedures have been advised on some occasions with limited discussion of
alternative treatments and with limited consideration of the suitability of the
woman for the specific type of surgery. A number of the submissions to the
committee were from women who had undergone transvaginal mesh surgery for the
treatment of SUI, despite presenting with only mild incontinence or no symptoms
Some women told the committee that they had been diagnosed and encouraged to
have surgery having attended for a routine pap-smear.
The committee was told of one case where a woman experienced debilitating
complications as a result of a device implanted just in case she later
Dr Jennifer King told the committee that transvaginal mesh procedures
should generally not be performed as a first line treatment in young women.
Dr King told the committee, that in the case of younger patients, medical
practitioners were more likely to suggest an alternative to a mesh implant:
For the younger ones, we say, 'Nothing's worked
conservatively. You've had it and you want an operation,' but I would
definitely try something simpler for the younger ones for fascial repair.
That's usually what we do.
However, the committee was concerned by some accounts received from
young women who had received mesh implants as first line treatment for their
For example, the committee was particularly concerned to learn of the
experiences of one woman who had received a tension-free vaginal tape (TVT)
implant to address mild SUI in 2008, when she was just 22 years old. Apart from
sessions in a Neotonus chair,
she was not offered alternative treatments. The surgeon advised her that TVT
surgery would be quick and that she was a prime candidate. She was not advised
of possible complications, or that the device was permanent. She recalls being
told 'that this was a new wonderful tension free tape that cures incontinence'
and she formed the impression that it was a small flexible tape that would
dissolve over time. The surgery was performed just six weeks after the birth of
her second child and she was not made aware that this could pose additional
risk. During her third pregnancy, doctors appeared unfamiliar with mesh
implants or how they might impact on her pregnancy.
I had to explain what a TVT was and they couldn't help me and
they told me there is no studies/research done for TVTs and pregnancy. All they
could say was that a C-section is recommended.
This woman has experienced recurrent urinary tract infections, pain and
bleeding after sex, but has been advised that these symptoms are not associated
with the implant. She has now been advised to have the mesh removed, once she
has finished having her family. She told the committee that she feels 'broken'
knowing that she is going to require a lot of medical assistance and support
for the rest of her life.
Information available to medical
A number of women questioned the information available to medical
practitioners to guide them in diagnosis of treatment options for SUI and POP.
A midwife who received a transvaginal mesh implant in 2005 to correct a
rectocele, questioned the use of synthetic mesh in the vagina, noting the
inherent elasticity of the organ. She expressed concern that there appears to
be a lack of communication between the specialist disciplines regarding the use
of transvaginal mesh procedures and evidence regarding complications.
RANZCOG advised that it provides statements on transvaginal mesh for SUI
and POP, but that these are intended as guidelines only and clinicians are
expected to understand the current literature regarding these procedures if
they are performing them.
The provision of information and training to medical practitioners is
considered further in Chapter 5.
Recognition of complications
Evidence to the inquiry suggests that in many cases women reporting
complications following transvaginal mesh surgery have experienced poor
responses from medical practitioners. The committee received many accounts
describing the challenges and frustration that patients have faced in having
their symptoms addressed, or indeed taken seriously. Dr Thierry Vancaillie told
My first observation is that almost all patients have seen
multiple physicians from various specialties, who either did not understand
them or simply did not believe them. Of the three patients I saw on Wednesday
last week, only one had received some treatment despite being in pain for at
least 14 months. One of the other patients was in pain for more than 10 years.
Sadly many women recounted being spoken to angrily or disrespectfully when
they have asked questions about their symptoms and spoke of feeling humiliated,
embarrassed and upset.
One woman told the committee that six months after her surgery, she began to
experience a range of symptoms for which tests failed to identify a cause. She
said that no one would believe her when she explained 'I have something
sticking out into my vagina.' Finally, after seeing a television program, she
consulted her doctor again and told him about the program
So he sent me back to my implanting gynaecologist, well he
just said nothing wrong with you I told him about the protruding mesh and he
said. It's working what more do you want. I told him about all the pain and did
he know about nerve damage. Don't know So for $200.00 I got nothing, no support
about how I was, he knew I was very upset. He gave me an internal, said
nothing, your fine it's working. I left in tears. As if I wasn't important.
Another woman told the committee that her surgeon dismissed her symptoms
and told her there was nothing further he could do for her:
This pain continued and I returned for my 6 week check up
where I was patted on the head and told that it would settle down. I returned
again to this dr who was more concerned with if I had commenced having sex. As
I didn't have a partner I was unable to answer that question. I spoke to him
about my constant pain in my coccyx, inability to sit or stand as I had a
terrible dragging feeling inside my abdomen down to my vagina. I had trouble
being able to lift my leg where I was told that he had no idea why I would have
that problem. Maybe I had fallen on my coccyx as a child and that was
resurfacing. I was again patted on the head and told maybe I was the 1% that
suffered pain from the procedure. I was told not to return there was nothing
else he could do for me.
One husband told the committee that his wife contacted her surgeon
regarding her symptoms, only to be told she was healing normally and to go home
and have sex.
Women reported being told that they were the only woman the surgeon had
treated who had experienced complications, that theirs was an unusual case or
that they were simply unlucky.
Other women have been told that their symptoms are imagined. For
example, one woman told of her frustration trying to find a doctor who 'knows
or understands what I am trying to say about what I am going through. They keep
telling me it's in my head.'
Others have had their symptoms dismissed as their body rejecting the device.
One woman reported being told: ' it was just me, it's my body rejecting the
device, I am the problem.'
Accounts received by the APMSG following recent publicity surrounding
mesh implants, suggest that women still meet with this type of dismissive and
disrespectful response. Ms Stella Channing, the Director and Administrator of
the APMSG, told the committee:
To add insult to injury, many women who have gone for
consultations have been scoffed at, mocked, humiliated and disregarded by some
of their doctors. These are some of the quotes: 'So you're one of those
following the hype.' Another: 'I went to a GP who told me not to believe all
the hype about mesh, and he wouldn't give me a referral to a specialist. He
sent me home with a sheet of back exercises to do. He then scoffed and said
that the doctor in Sydney will be driving around in luxury cars paid for by
ladies like myself. I felt humiliated.'
Another: 'My doctor told me that my mesh wasn't the issue and
only a few women are having problems. He told me not to believe all the drama
that is going on in the media and online.'
Ms Channing told the committee that such comments are an invalidation of
women's lived experience. She said that such responses demonstrate 'how the
health system silences, shames and blames the victims.'
The APMSG told the committee that some women have driven significant
distances or have flown interstate in search of doctors who willing and able to
Women told the committee of their relief when they finally found a practitioner
who was willing to provide understanding and support:
Finally just to meet a specialist who gave belief,
understanding and hope was a pure god send in knowing I was not alone and my
story was real.
Practitioner's knowledge of
Some submitters expressed concern that the medical practitioners they
approached seemed unaware of the symptoms associated with mesh implants. Ms
Stella Channing, from the APMSG told the committee that one of the difficulties
is that women often approach their GP in the first instance, who may have no
understanding of complications associated with transvaginal mesh:
What happens is that women who are suffering with their pain
and complications such as mesh erosion or they are bleeding go to their
doctor—and, to be honest it starts at the GP level. The GPs don't understand
mesh or mesh complications and the women are usually fobbed off. They might be
sent for a scan or an x-ray and they are sent away. The X-ray comes back with
nothing and then the doctor says, 'There's nothing wrong with you' because they
don't show anything. Women go back again and again to doctors and they are
being sent away, and doctors are saying, 'We don't know what it is.' Some women
go on for years in that same cycle...
Women told the committee of the frustration and stress caused by delays
in identifying and treating symptoms. In other cases, the length of time taken
to identify and treat symptoms women were experiencing was a cause of
frustration and stress. Andrea told the committee:
I began to dread attending the GP for fear of being made to
feel a hypochondriac, again dismissed and told it was very unlikely my symptoms
were due to the mesh, and all the hype on the internet was not to be believed
Another woman provided the committee with a timeline spanning two years
during which she presented with a range of symptoms, including: pelvic pain;
difficulty voiding; urinary tract infections and ineffectual emptying of her
bladder. She raised suspicions that her symptoms were related to her
transvaginal mesh device, but it took another 12 months before her surgeon
suggested that this might be the case. She was advised that she was the only
patient her surgeon had with complications and states that at various points
she felt her surgeon was stalling and not taking her symptoms seriously. She
was concerned that it took more months before the surgeon proposed a
Evidence to the committee stressed the importance of medical
practitioners having some awareness of the transvaginal mesh procedures and the
possible complications that may arise. As one woman wrote:
All doctors need to [be] aware of the complications and
adverse effects of transvaginal mesh and be open to what their patients are
telling them. The specialists need to keep up with the current research so that
at an early stage the problems could be dealt with rather than them being left
leading to chronic life altering conditions. It should not be a closed shop for
gynaecologists and urogynaecologists as the complicatiosn are far reaching
across all specialities.
Mrs Charlotte Korte, representing the New Zealand support group, Mesh
Down Under, told the committee it is remarkable that the way women with mesh
complications are being treated by doctors has not changed. She said that many
doctors are still not trained to recognise mesh injuries and that this needed
to be urgently addressed to cut the time it takes to diagnose mesh related complications.
Noting that GPs are often a primary point of contact with the medical
profession for many patients, the committee sought to understand the steps
being taken to ensure that GPs were aware of mesh related symptoms. Dr
Magdalena Simonis, of the Royal Australian College of General Practitioners
(RACGP), explained the challenges faced by GPs in treating women who present
with pelvic pain or other symptoms following mesh procedures. Dr Simonis noted
that the GP is often not in a position to know that the woman has had a mesh
procedure due to the lag between the procedure and the onset of complications:
One of the issues is that the time line of presentation
between surgery and presentation with complaints of pain could be anything from
weeks to several years. Some patients might not have continuity of care with
the same GP. Sometimes the GP has not been made aware of the details of the
actual surgery that the woman had; even if the woman has had surgical
interventions by a surgeon whom the GP has referred them to.
One of the complicating factors in identifying mesh related
complications is the delay in the onset of symptoms. As noted elsewhere, it can
be some years before women begin to experience problems associated with their
In addition, the range of symptoms that women experience may not be easily
identified as related to a transvaginal mesh implant. As one woman explained:
Despite having my GP, gynecologist and neurosurgeon all
trying to help sort out the source of my pain, nobody, seemed to know anything
about mesh complications. The problem with women talking to doctors about mesh
implants is that when you begin to experience these side effects you have no
idea that it could even be related to the mesh. The debilitating pain etc
presents itself in a way that makes you think it could be your hip, back or
legs? I had countless spinal and nerve blocks, Xrays, MRI's and Cat Scans. I
spent years on the medical merry-go-round. When these results are always
coming back negative and nothing is being diagnosed the medical professionals
start to treat you like you are crazy or deluded. I don't think there is
enough education of these doctors to the reality of transvaginal mesh implant
Dr Simonis told the committee that this poses particular challenges for
GPs who are often less familiar with the complexities of mesh related
There has been a lag between the surgery and the
complications, which is the case in many of these situations where the lag has
been so long. And it is very unfortunate that the woman (sic) who have been
interviewed have actually had the experiences that they've had. As a college,
we take that on board and we'll need to really inform our GP community of the
reality and the complexity of pelvic pain and how prior surgery may well be one
of the reasons for this.
Dr Simonis told the committee that GPs are now aware of the need to specifically
ask if the patient has had a vaginal mesh procedure:
I think that's what we've not been aware of to date, and this
has certainly brought this to our attention.
The committee notes recommendations for greater education of GPs, nurses
and medical clinics about complications associated with transvaginal mesh so
that they are better able to provide or refer patients for appropriate
treatment and support. Some women advocated the establishment of specialist
clinics to provide support in pain management and other complications
associated with mesh implants.
For the future: I'd like to see my local doctors, nurses and
medical clinics become more educated and become more aware of TVT issues. It
would be great if a local mesh clinic is established focusing on pain
management, life management, free removal and aides, and help with all the
other problems associated that I'm trying to live with. But at the moment my
options are limited. In my opinion TVT should be banned or at the very least be
limited to a last resort option, with all warnings given to patients prior.
Follow up and on-going monitoring
A number of women expressed concern that there was limited or no follow
up after their surgery.
Women told the committee that there should be comprehensive follow up after
surgery, to document the progress of each patient and treat complications as
One woman who had transvaginal mesh surgery for POP in 2006 told the committee:
I believe there needs to be monitoring of women who have had
these devices implanted, and comprehensive follow up at regular intervals 6
weeks 3 months 12 months and annually from there after, so that a comprehensive
data base can be created to monitor the actual numbers of women who experience
these complications, and so that we can have a clearer picture to the outcome
of these issues at present nothing like this exists.
The committee received evidence regarding surgical audits and research
studies that have tracked the progress of women after surgery. For example, Professor
Peter Dwyer, speaking on behalf of the tertiary referral Urogynaecology Units
at both the Mercy Hospital for Women and Monash Health told the committee that
those units follow up all of their mesh patients 'to look at their outcomes and
to look at complications associated with them'. Professor Dwyer clarified that
this follow up is partly a surgical audit and partly for research purposes.
The results of this work have been published, including:
a five year follow up study of 1225 consecutive women who
underwent a MUS between 1999 and 2007, published in 2010, indicated an 86
percent subjective cure rate for SUI;
a study of sexual function following MUS, published in 2011,
indicated a reduction in urinary leakage and fear of leakage during sex; and
a five year follow up of a randomised controlled trial comparing
a single incision MUS with a transobturator MUS in 235 women, published in
2017, revealed a greater that 95 percent cure rate and less than 1 percent
Dr Anna Rosamilia, a urogynaecologist at Monash Health's tertiary referral
centre, told the committee that surgical audit and follow up conducted at
Monash Health and is used to inform patient counselling and discussion prior to
surgery. By way of example, Dr Rosamilia told the committee that by doing audit
and follow-up, Monash Health had identified that the risk of mesh exposure had
decreased, possibly due to a changes in materials but also experience and
changes in surgical technique.
As noted in Chapter 2 and Chapter 3, a number of women have undergone
procedures for the removal of transvaginal mesh devices. Some of these have
travelled overseas for this surgery, at significant cost and continue to face
debts associated with this.
A number of other women advised the committee that they were intending to have surgery
to remove their implants.
Some women wrote that they had been advised their mesh could not be
removed safely without risking further complications.
Others told the committee that they have heard that there are no surgeons in
Australia who could remove mesh safely or that are appropriately skilled to
undertake such surgery,
and that if they wished to have their mesh implant removed, their only option
would be to travel overseas to have this surgery.
RANZCOG advised the committee that the risks associated with mesh
removal are 'not insignificant' and that the risks associated with full mesh
removal may exceed the possible benefit. RANZCOG submitted:
If the mesh has eroded into bladder and/or bowel, a combined
surgical team with urogynaecologist/gynaecologist and urologist and/or
colorectal surgeon may be required. Whilst the mesh can be removed, it cannot
always be safely removed completely, and the long-term pain associated with
mesh may not be completely resolved despite mesh removal.
Some women have told the committee of positive outcomes following full
or partial removal of their mesh. However, the experiences of some of the women
who have had their mesh removed indicate that they continue to live with
significant complications. For example, one woman who had a full mesh removal
in Australia in 2017 wrote:
While feeling better that the mesh has been removed I am left
with pudendal nerve damage, fibromyalgia, inability to sit or stand for any
length of time, inability to be intimate or have sexual relations with my
husband, inability to pursue an active lifestyle, and the inability to attend
regular family functions (sport practices/events, movies, dinners,
parent/teacher conferences, etc.) due to the pain in my vaginal and gluteal
RANZCOG stated that it is appropriate in such circumstances to inform
women that the mesh cannot be removed safely. RANZCOG noted that 'some women
may misconstrue this advice as meaning that the mesh cannot be removed because
Australian Urogynaecologists are not trained in mesh removal, and believe they
must seek a surgical solution overseas or wait for an overseas trained
Urogynaecologist to come to Australia to perform and teach mesh removal.'
The committee heard that there are a number of surgical units in Australia
that have expertise to undertake mesh excision and that further units are in
the process of gaining expertise from overseas surgical facilities.
Professor Vancaillie told the committee that medical practitioners
needed to improve their knowledge of chronic pain and the way they respond to
it. He said that where severe pain occurs immediately after insertion of a
transvaginal mesh device, the device should be removed immediately. However, if
the pain occurs with delay, then the pain should be managed first and if that
is unsuccessful, the mesh should be removed. Professor Vancaillie said that in
his experience, there is a fifty percent chance that pain will be immediately
significantly better after removal of the device and a 50 percent chance that it
will still take some time to control the pain.
The committee is deeply concerned by the accounts it has received of women's
experiences at the hands of medical practitioners. Even allowing for the
positive accounts provided to the committee and the fact that some accounts are
recalling events of over ten or fifteen years ago, they present the medical
profession in a very poor light.
The committee considers that informed consent is fundamental in the
provision of healthcare. The committee notes the guidance provided by RANZCOG
to support informed consent and the evidence provided by specialist urology and
gynaecology units regarding the comprehensive nature of pre-operative
counselling provided in those units. However, the committee is concerned that
the vast majority of personal accounts received from women indicate a lack of
consistency and care in eliciting women's consent prior to transvaginal mesh
The committee is concerned that in many cases women's consent has been
obtained following a perfunctory or generic discussion of the risks involved. In
many cases, no alternate measures have been discussed. The committee is
particularly concerned by accounts of women receiving transvaginal mesh
implants without their knowledge. The committee considers that informed consent
must involve discussion and understanding of the risks and benefits specific to
the individual patient and the procedure they are being offered. Simply
providing a patient with a form to sign is not sufficient.
The committee is concerned about the apparent inconsistency in the care
with which the initial diagnosis of women's conditions has been undertaken. The
committee notes the evidence regarding rigorous systems in place in specialist
units. However, the committee is deeply troubled by personal accounts which
reflect diagnosis made following limited examination and the recommendation of
transvaginal mesh procedures as a first line response to reportedly minor SUI
From reading the personal accounts received from individual women, the
committee considers there is a need for clear and accessible information about
complications associated with transvaginal mesh procedures, and options for
addressing these, for both patients and medical practitioners. In particular,
there is a need for clear guidance in relation to options for partial or full
removal of transvaginal mesh. The committee will consider this further in the
Finally, the committee is concerned at the response of some medical
practitioners to women presenting with complications. The committee appreciates
a range of factors can complicate a medical practitioner's ability to quickly
and accurately identify the underlying cause of symptoms. However, the
committee can find no reasonable justification for the dismissive and
disrespectful treatment many women have experienced from trusted medical
The committee encourages women not to accept unprofessionalism by
medical practitioners and to consider reporting any concerns they might have, either
to the medical practice or hospital, or in the case of more serious complaints,
to the health care ombudsman in the relevant state.
Navigation: Previous Page | Contents | Next Page